CA3041599A1 - Composition for the preventive or curative treatment of liver disorders - Google Patents
Composition for the preventive or curative treatment of liver disorders Download PDFInfo
- Publication number
- CA3041599A1 CA3041599A1 CA3041599A CA3041599A CA3041599A1 CA 3041599 A1 CA3041599 A1 CA 3041599A1 CA 3041599 A CA3041599 A CA 3041599A CA 3041599 A CA3041599 A CA 3041599A CA 3041599 A1 CA3041599 A1 CA 3041599A1
- Authority
- CA
- Canada
- Prior art keywords
- bifidobacterium
- germany
- probiotical
- deposit
- deposited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000003449 preventive effect Effects 0.000 title claims abstract description 12
- 238000009109 curative therapy Methods 0.000 title claims description 10
- 208000019423 liver disease Diseases 0.000 title description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 89
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 38
- 241000894006 Bacteria Species 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 206010019842 Hepatomegaly Diseases 0.000 claims abstract description 11
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 10
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 10
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 9
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 30
- 230000001580 bacterial effect Effects 0.000 claims description 30
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 26
- 241000894007 species Species 0.000 claims description 24
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 22
- 241001608472 Bifidobacterium longum Species 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 9
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 241000266824 Oscillospira Species 0.000 claims description 5
- 101000592939 Bacillus subtilis (strain 168) 50S ribosomal protein L24 Proteins 0.000 claims description 4
- 101001070329 Geobacillus stearothermophilus 50S ribosomal protein L18 Proteins 0.000 claims description 4
- 239000006041 probiotic Substances 0.000 abstract description 8
- 230000000529 probiotic effect Effects 0.000 abstract description 8
- 235000018291 probiotics Nutrition 0.000 abstract description 8
- 241000186000 Bifidobacterium Species 0.000 description 28
- 150000002500 ions Chemical class 0.000 description 15
- 241000186660 Lactobacillus Species 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 244000005709 gut microbiome Species 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 240000001929 Lactobacillus brevis Species 0.000 description 4
- 241000394636 Lactobacillus mucosae Species 0.000 description 4
- 241000577554 Lactobacillus zeae Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 208000027244 Dysbiosis Diseases 0.000 description 3
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 3
- 241000186870 Lactobacillus ruminis Species 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007140 dysbiosis Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 244000005702 human microbiome Species 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000605059 Bacteroidetes Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241001143779 Dorea Species 0.000 description 1
- 206010015107 Epstein-Barr viral infections Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010057212 Hepatitis viral infections Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010068237 Hypertransaminasaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007301 hepatic immune response Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
The present invention relates to a composition comprising probiotic bacteria for the curative or preventive treatment of metabolic syndrome, enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject, and a pharmaceutical preparation or medical device or food supplement comprising said composition.
Description
DESCRIPTION of an invention having the title:
"Composition for the preventive or curative treatment of liver disorders"
The present invention relates to a composition (C) comprising probiotic bacteria of the genus Bifidobacterium for the curative or preventive treatment of liver disorders, particularly in subjects of paediatric age, and to a pharmaceutical preparation or medical device comprising said composition.
Paediatric non-alcoholic fatty liver disease (NAFLD) may progress from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH).
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in adults and children. It is considered to be a set of liver conditions ranging from fatty liver to non-alcoholic steatohepatitis (NASH) with or without fibrosis. The pathogenesis of NAFLD has been partially clarified and it is generally believed that, from a pathological standpoint, it is a multi-factor disease. This assumption is based on the central role of the high circulating levels of free fatty acids (FFAs) and insulin resistance, which can interact with each other, causing an accumulation of FFAs in hepatocytes (non-alcoholic fatty liver, NAFL), oxidative stress and inflammatory response, thus providing the basis for the progression of liver damage.
It is interesting to note that various studies shown that intestinal microbiota may also play an important role in the development and progression of NAFLD. In the context of the present invention, "microbiota" means the ecological community of commensal, symbiotic and pathogenic microorganisms that literally share the space of our body and the internal cavities thereof. Human microbiota consists of about 100 trillion microbial cells which exceed human cells in a ratio of 100 to 1, with five phyla representing the majority of the community. About 160 species have been found in the large intestine of each individual and very few of them are shared by individuals who are not related. It has been demonstrated that the microbiota composition can influence the proportion of calories absorbed by intestinal contents.
In fact, bacteria play an important role in the absorption and emulsion of fats and liposoluble vitamins in the small intestine. Intestinal microbiota can also produce endotoxins, such as lipopolysaccharide (LPS), which, in a condition of compromised intestinal permeability, can reach the circulatory system, leading to an intra- and extrahepatic inflammatory response, which in turn induces a progression from fatty liver to NASH.
Intestinal microbiota is influenced by diet, age, infections, hygienic habits and antibiotic therapy. Patients affected by NAFLD have shown a high prevalence of small intestine bacterial overgrowth (SIBO) and a greater intestinal permeability, which favours bacterial translocation, exposing the liver to toxic microbial metabolites. Obese patients affected by NAFLD have shown a reduction in Bacteroidetes and an increase in Firmicutes compared to patients of normal weight.
Surprisingly, the weight loss due to a limited intake of carbohydrates and fats increases the prevalence of Bacteroidetes in the intestinal microbiota.
Furthermore, studies on mice affected by NAFLD have demonstrated that some probiotic bacteria reduce the concentration of cholesterol in plasma and protect against the accumulation of fats in adipose tissue and hepatocytes.
Although recent studies have highlighted that intestinal microbiota have a role in the pathogenesis of NAFLD, how such results may improve therapy remains to be clarified.
An understanding of the nature of intestinal dysbiosis, the integrity of the intestinal barrier and the mechanisms of the hepatic immune response to intestine-derived factors is potentially relevant for the development of new therapies for the treatment of chronic liver diseases.
The term "dysbiosis" was coined by Metchnikoff in 1907 to describe altered pathogenic bacteria in the intestine. Dysbiosis has been defined as indicative of the qualitative and quantitative changes in the intestinal flora and in the metabolic and local distribution thereof.
In a recent in-depth characterisation of the intestinal microbiotic profile of children affected by NAFLD
versus obese and thin children without liver disease it emerged that Ruminococcus and Dorea increase in concomitance with the progression of NAFL towards NASH.
However, the therapies presently available for the treatment and/or prevention of NAFLD in order to avoid its progression to NASH and for the curative treatment of NASH are based on radical modifications of the diet, the administration of drugs that act on glycaemia (metformin and thiazolidinediones) or statins, or surgical weight reduction (bariatric surgery).
There is thus a felt need to provide a treatment for NAFLD and/or NASH, above all in subjects of paediatric age (0-18 years), which has a low impact on lifestyle, does not require surgical intervention and is practically free of the side effects normally associated with the above-mentioned pharmacological treatments.
In response to this need, the present invention provides a composition (C) which comprises an effective amount of a mixture comprising, or consisting of, at least one bacterial strain belonging to at least one species selected from the group comprising, or, alternatively, consisting of Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum, for use in the preventive and/or curative
"Composition for the preventive or curative treatment of liver disorders"
The present invention relates to a composition (C) comprising probiotic bacteria of the genus Bifidobacterium for the curative or preventive treatment of liver disorders, particularly in subjects of paediatric age, and to a pharmaceutical preparation or medical device comprising said composition.
Paediatric non-alcoholic fatty liver disease (NAFLD) may progress from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH).
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in adults and children. It is considered to be a set of liver conditions ranging from fatty liver to non-alcoholic steatohepatitis (NASH) with or without fibrosis. The pathogenesis of NAFLD has been partially clarified and it is generally believed that, from a pathological standpoint, it is a multi-factor disease. This assumption is based on the central role of the high circulating levels of free fatty acids (FFAs) and insulin resistance, which can interact with each other, causing an accumulation of FFAs in hepatocytes (non-alcoholic fatty liver, NAFL), oxidative stress and inflammatory response, thus providing the basis for the progression of liver damage.
It is interesting to note that various studies shown that intestinal microbiota may also play an important role in the development and progression of NAFLD. In the context of the present invention, "microbiota" means the ecological community of commensal, symbiotic and pathogenic microorganisms that literally share the space of our body and the internal cavities thereof. Human microbiota consists of about 100 trillion microbial cells which exceed human cells in a ratio of 100 to 1, with five phyla representing the majority of the community. About 160 species have been found in the large intestine of each individual and very few of them are shared by individuals who are not related. It has been demonstrated that the microbiota composition can influence the proportion of calories absorbed by intestinal contents.
In fact, bacteria play an important role in the absorption and emulsion of fats and liposoluble vitamins in the small intestine. Intestinal microbiota can also produce endotoxins, such as lipopolysaccharide (LPS), which, in a condition of compromised intestinal permeability, can reach the circulatory system, leading to an intra- and extrahepatic inflammatory response, which in turn induces a progression from fatty liver to NASH.
Intestinal microbiota is influenced by diet, age, infections, hygienic habits and antibiotic therapy. Patients affected by NAFLD have shown a high prevalence of small intestine bacterial overgrowth (SIBO) and a greater intestinal permeability, which favours bacterial translocation, exposing the liver to toxic microbial metabolites. Obese patients affected by NAFLD have shown a reduction in Bacteroidetes and an increase in Firmicutes compared to patients of normal weight.
Surprisingly, the weight loss due to a limited intake of carbohydrates and fats increases the prevalence of Bacteroidetes in the intestinal microbiota.
Furthermore, studies on mice affected by NAFLD have demonstrated that some probiotic bacteria reduce the concentration of cholesterol in plasma and protect against the accumulation of fats in adipose tissue and hepatocytes.
Although recent studies have highlighted that intestinal microbiota have a role in the pathogenesis of NAFLD, how such results may improve therapy remains to be clarified.
An understanding of the nature of intestinal dysbiosis, the integrity of the intestinal barrier and the mechanisms of the hepatic immune response to intestine-derived factors is potentially relevant for the development of new therapies for the treatment of chronic liver diseases.
The term "dysbiosis" was coined by Metchnikoff in 1907 to describe altered pathogenic bacteria in the intestine. Dysbiosis has been defined as indicative of the qualitative and quantitative changes in the intestinal flora and in the metabolic and local distribution thereof.
In a recent in-depth characterisation of the intestinal microbiotic profile of children affected by NAFLD
versus obese and thin children without liver disease it emerged that Ruminococcus and Dorea increase in concomitance with the progression of NAFL towards NASH.
However, the therapies presently available for the treatment and/or prevention of NAFLD in order to avoid its progression to NASH and for the curative treatment of NASH are based on radical modifications of the diet, the administration of drugs that act on glycaemia (metformin and thiazolidinediones) or statins, or surgical weight reduction (bariatric surgery).
There is thus a felt need to provide a treatment for NAFLD and/or NASH, above all in subjects of paediatric age (0-18 years), which has a low impact on lifestyle, does not require surgical intervention and is practically free of the side effects normally associated with the above-mentioned pharmacological treatments.
In response to this need, the present invention provides a composition (C) which comprises an effective amount of a mixture comprising, or consisting of, at least one bacterial strain belonging to at least one species selected from the group comprising, or, alternatively, consisting of Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum, for use in the preventive and/or curative
2 treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome, enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject, wherein said treatment comprises oral administration of said composition (C) to the subject.
The present invention responds to said need, moreover, by means of a pharmaceutical preparation or medical device or food supplement comprising a composition (C) which comprises (i) a mixture comprising, or consisting of, at least one bacterial strain belonging to at least one species selected from the group comprising, or, alternatively, consisting of Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum and (ii) at least one excipient suitable for pharmaceutical and/or food use.
It has surprisingly been found that strains of probiotic bacteria of the genus Bifidobacterium, in particular the strains of probiotic bacteria belonging to the species Bifidobacterium adolescent/s, Bifidobacterium bifidum and Bifidobacterium Ion gum, are effective as a treatment for subjects affected by NAFLD and/or NASH, above all subjects of paediatric age.
The present invention relates to bacterial strains belonging to the species B.
adolescentis selected from the group comprising or, alternatively, consisting of: (i) Bifidobacterium adolescentis BA06, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32479; and (ii) Bifidobacterium adolescentis BA07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A.
on 21.4.2017 and having the deposit no. 32491.
The present invention relates to bacterial strains belonging to the species B.
bifidum selected from the group comprising or, alternatively, consisting of: (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32480; and (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32481.
The present invention relates to bacterial strains belonging to the species B.
Ion gum selected from the group comprising or, alternatively, consisting of: (v) Bifidobacterium Ion gum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32482; and (vi) Bifidobacterium Ion gum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32483.
Advantageously the bacterial strains belonging to the above-mentioned species Bifidobacterium adolescent/s, Bifidobacterium bifidum and Bifidobacterium Ion gum, indicated as (i) to (vi), are for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said strains to the subject.
The present invention responds to said need, moreover, by means of a pharmaceutical preparation or medical device or food supplement comprising a composition (C) which comprises (i) a mixture comprising, or consisting of, at least one bacterial strain belonging to at least one species selected from the group comprising, or, alternatively, consisting of Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum and (ii) at least one excipient suitable for pharmaceutical and/or food use.
It has surprisingly been found that strains of probiotic bacteria of the genus Bifidobacterium, in particular the strains of probiotic bacteria belonging to the species Bifidobacterium adolescent/s, Bifidobacterium bifidum and Bifidobacterium Ion gum, are effective as a treatment for subjects affected by NAFLD and/or NASH, above all subjects of paediatric age.
The present invention relates to bacterial strains belonging to the species B.
adolescentis selected from the group comprising or, alternatively, consisting of: (i) Bifidobacterium adolescentis BA06, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32479; and (ii) Bifidobacterium adolescentis BA07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A.
on 21.4.2017 and having the deposit no. 32491.
The present invention relates to bacterial strains belonging to the species B.
bifidum selected from the group comprising or, alternatively, consisting of: (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32480; and (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32481.
The present invention relates to bacterial strains belonging to the species B.
Ion gum selected from the group comprising or, alternatively, consisting of: (v) Bifidobacterium Ion gum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32482; and (vi) Bifidobacterium Ion gum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32483.
Advantageously the bacterial strains belonging to the above-mentioned species Bifidobacterium adolescent/s, Bifidobacterium bifidum and Bifidobacterium Ion gum, indicated as (i) to (vi), are for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said strains to the subject.
3 The composition for use according to the present invention may further be used advantageously in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver.
In one embodiment, the composition Cl of the present invention comprises a mixture of bacteria which comprises or, alternatively, consists of the bacterial strains (i) + (iii) +
(v) and, optionally, suitable pharmaceutical and/or food grade excipients, preferably in a ratio by weight of 1:1:1, for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said composition to the subject.
In another embodiment, the composition C2 of the present invention comprises a mixture of bacteria which comprises or, alternatively, consists of the bacterial strains (ii) + (iv) +
(vi) and, optionally, suitable pharmaceutical and/or food grade excipients, preferably in a ratio by weight of 1:1:1, for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said composition to the subject.
In another embodiment, the composition 03 of the present invention comprises a mixture of bacteria which comprises or, alternatively, consists of the bacterial strains [(i)+(ii)] +
[(iii)+(iv)] + [(v)+(vi)], and, optionally, suitable pharmaceutical and/or food grade excipients, preferably in a ratio by weight of 1:1:1 ([(i)+(ii)] :
[(iii)+(iv)] : [(v)+(vi)]), for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said composition to the subject.
In the context of the present invention, metabolic syndrome (also called syndrome X, insulin resistance syndrome, CHAOS, in Australia, or Reaven's syndrome) means a clinical situation of high cardiovascular risk which comprises a series of risk factors and symptoms that manifest themselves simultaneously in an individual. These are often correlated to the person's lifestyle (excessive weight, sedentary life) or pre-existing pathological situations (obesity, hypercholesterolaemia ¨ presence of a high blood cholesterol level, etc.) .
The definition most widely known and applied in clinical practice is that of the National Cholesterol Education Program Adult Treatment Panel (ATP) Ill of 2001. It does not consider any direct or indirect diagnostic element of insulin resistance, but envisages the simultaneous presence of three variables
In one embodiment, the composition Cl of the present invention comprises a mixture of bacteria which comprises or, alternatively, consists of the bacterial strains (i) + (iii) +
(v) and, optionally, suitable pharmaceutical and/or food grade excipients, preferably in a ratio by weight of 1:1:1, for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said composition to the subject.
In another embodiment, the composition C2 of the present invention comprises a mixture of bacteria which comprises or, alternatively, consists of the bacterial strains (ii) + (iv) +
(vi) and, optionally, suitable pharmaceutical and/or food grade excipients, preferably in a ratio by weight of 1:1:1, for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said composition to the subject.
In another embodiment, the composition 03 of the present invention comprises a mixture of bacteria which comprises or, alternatively, consists of the bacterial strains [(i)+(ii)] +
[(iii)+(iv)] + [(v)+(vi)], and, optionally, suitable pharmaceutical and/or food grade excipients, preferably in a ratio by weight of 1:1:1 ([(i)+(ii)] :
[(iii)+(iv)] : [(v)+(vi)]), for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to metabolic syndrome and enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said composition to the subject.
In the context of the present invention, metabolic syndrome (also called syndrome X, insulin resistance syndrome, CHAOS, in Australia, or Reaven's syndrome) means a clinical situation of high cardiovascular risk which comprises a series of risk factors and symptoms that manifest themselves simultaneously in an individual. These are often correlated to the person's lifestyle (excessive weight, sedentary life) or pre-existing pathological situations (obesity, hypercholesterolaemia ¨ presence of a high blood cholesterol level, etc.) .
The definition most widely known and applied in clinical practice is that of the National Cholesterol Education Program Adult Treatment Panel (ATP) Ill of 2001. It does not consider any direct or indirect diagnostic element of insulin resistance, but envisages the simultaneous presence of three variables
4 among the following: abdominal obesity, hypertension, hypertriglyceridaemia, low HDL cholesterol and glycaemia >110 mg/di (also including diabetes).
In the context of the present invention, "enlarged liver", or hepatomegaly, means an increase in the size of the liver compared to what is judged clinically normal for an individual; it may be detected, for example, by palpation, exams with techniques such as ultrasound or computed tomography (CT) and/or blood tests.
The compositions for use according to the present invention, such as, for example, compositions Cl, 02 and 03 can be advantageously used, moreover, in obese or overweight subjects, according to the definition of the World Health Organisation, i.e. with a body mass equal to or greater than 25 to 29.99 (overweight) or equal to or greater than 30 (obese), preferably in paediatric age.
In one aspect of the invention, the composition (C), such as, for example, compositions Cl, C2 and C3, are administered to subjects at the risk of developing NAFLD and/or NASH, even if they do not yet have all the symptoms of said pathologies.
Preferably, the composition (C), such as, for example, compositions Cl, 02 and 03 for use according to the present invention, comprise a mixture of bacterial strains belonging to a species selected from the group consisting of, or, alternatively, comprising each species Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum, i.e. in which bacteria of at least all said species are present.
Preferably, the composition (C), such as, for example, compositions Cl, 02 and 03 for use according to the invention, may further comprise bacterial strains belonging to the genus Oscillospira.
In one aspect, the present invention provides a pharmaceutical preparation or medical device or food supplement comprising a composition (C) which comprises (i) a mixture of at least one bacterial strain belonging to at least one species selected from among the group comprising, or, alternatively, consisting of, bacteria belonging to at least one species among Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum and (ii) at least one excipient suitable for pharmaceutical and/or food use.
Preferably, in the pharmaceutical preparation or medical device or food supplement according to the present invention, the mixture (i) of the composition (C), such as, for example, of compositions Cl, 02 and 03, comprises a mixture of bacterial strains belonging to a species selected from the group consisting of or, alternatively, comprising each species Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum, and (ii) at least one excipient suitable for pharmaceutical and/or food use, i.e.
where bacteria belonging to at least each of said species are present.
Preferably, in the pharmaceutical preparation or medical device or food supplement according to the present invention, the mixture (i) of the composition (C), such as, for example, of compositions Cl, 02 and 03, further comprises bacteria belonging to the genus Oscillospira .
The at least one excipient (ii) suitable for pharmaceutical and/or food use may be selected from among all the substances known to the person skilled in the pharmaceutical field or the field of food preparations, including, as non-limiting examples, preservatives, thickeners, sweeteners, colourants, natural and artificial flavouring, antioxidants, stabilisers, fillers and mixtures thereof.
In the context of the present invention, the pharmaceutical preparation or medical device or food supplement may further comprise at least one pharmaceutically active ingredient or bacteria belonging to a species other than Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum .
The following examples are provided to illustrate practical aspects of implementation, without any intention of limiting the scope hereof.
Bifidobacteria and lactobacilli were analysed by pyrosequencing of 16S rRNA in stool samples taken from 61 obese children with NAFL and NASH and 54 healthy controls.
Three species of Bifidobacterium (Bifidobacterium Ion gum, Bifidobacterium bifidum, Bifidobacterium adolescentis) and five species of Lactobacillus (Lactobacillus zeae, Lactobacillus vaginalis, Lactobacillus brevis, Lactobacillus ruminis, Lactobacillus mucosae) were frequently found in the metagenomic analyses.
The species of Lactobacillus were in greater number in the subjects affected by NAFL, with or without NASH, than in the controls, whilst bifidobacteria were frequent in healthy subjects.
MATERIALS AND METHODS
The study was conducted on 61 consecutive overweight or obese children (35 males, age 11.45 2.42 years) monitored at the Department of Hepato-Metabolic Diseases (Rome, Italy) of the Bambino Gesu Paediatric Hospital and Research Institute (OPBG) in 2013. All patients underwent testing for secondary causes of fatty liver, such as hepatitis, cytomegalovirus and Epstein-Barr viral infections, liver disease, autoimmune diseases, metabolic liver disease, Wilson's disease, coeliac disease and alpha-1-antitrypsin deficiency, which were ruled out using standard histological, laboratory and clinical criteria. Fifty-three patients, with a BMI>95th percentile, and/or hypertransaminasaemia and steatosis, underwent a liver biopsy for the assessment of liver damage. The study population was made up of 3 groups: 8 (13.12%) obese, 27 (44.26%) with NAFLD and 26 (42.62%) with defined NASH. Furthermore, 54 healthy children of a corresponding age, enrolled at the Human Microbiome Unit of the OPBG, were used as controls (control subjects).
The hospital's research ethics committee approved the study, which was conducted in conformity with the Declaration of Helsinki (according to the revision of Seoul, Korea, October 2008). The parents of the enrolled subjects gave informed written consent. The study was approved by the ethics committee of the OPBG (reference no. 768.12).
Stool samples were collected from all of the affected children and control subjects and analysed at the Human Microbiome Unit of the OPBG.
Anthropometric and laboratory analyses Anthropometric parameters including weight, height, BMI and waist circumference were measured in all of the children using standardised methods. Obesity was defined as a BMI 95th percentile, adjusted for age and sex according to WHO growth graphs. Fasting plasma glucose (FPG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), y-glutamyltransferase (GGT), fasting serum triglycerides (TG) and total cholesterol levels were determined using standardised methods in our laboratory. Insulin was measured by means of radioimmunoassay (MYRIA Technogenetics, Milan, Italy).
The degree of insulin resistance/sensitivity was determined by evaluating the homeostatic model (HOMA).
A HOMA value > 2 was considered indicative of insulin resistance.
All of the patients underwent abdominal ultrasound examination.
Designated expert radiologists, unaware of the clinical conditions of the patients, performed a liver ultrasound scan after overnight fasting.
The liver was analysed in terms of fatty liver markers using established criteria: a bright liver echostructure (compared with the echo response of the right kidney).
DNA extraction Each stool sample collected from the 115 children underwent a further metagenomic analysis having 16S-rRNA as the target. DNA was extracted from each sample using the QIAamp DNA
Stool Mini Kit (Qiagen, Germany).
The stools were resuspended in 1.5 ml PBS, rendered homogeneous by mixing for 2 minutes and centrifuged at 20,800xg. After removal of the supernatant, the sediment was resuspended in 500 pl of PBS, to which 500 pl of beads/PBS were added (1 mg/pl, w/v) (acid-washed glass beads, SigmaAldrich).
The supernatant was collected and treated for one freeze/thaw cycle (-20 0/70 C) for 20 minutes in each phase as previously described. After centrifugation at 5,200xg for 5 minutes, the supernatant was subjected to extraction with the QIAamp DNA Stool Mini Kit (Qiagen, Germany) according to the manufacturer's instructions and subsequently subjected to a metagenomic analysis pipeline. The intestinal microbiome was examined by pyrosequencing the V1-V3 regions of the 16S rRNA
gene (amplicon size 520 bp), on a GS Junior platform (454 Life Sciences, Roche Diagnostics, Italy).
Results The analysis revealed a prevalent distribution of 3 main species of Bifidobacterium (Bifidobacterium Ion gum, Bifidobacterium bifidum, Bifidobacterium adolescentis) and 5 species of Lactobacillus (Lactobacillus zeae, Lactobacillus vagina/is, Lactobacillus brevis, Lactobacillus ruminis, Lactobacillus mucosae), which appeared in a different manner in the targeted metagenomic analyses. In particular, L.
zeae was present in all four groups (i.e. obese, control ¨CTRL-, NAFL and NASH
children), whereas L
ruminis and L. vagina/is were present only in the NAFL and NASH groups. L.
mucosae was associated with obesity and NAFL, and L. brevis with NASH and control subjects (Figure 1).
In contrast, an inverse correlation was observed between bifidobacteria and NAFL and NASH; in particular, although the species B. Ion gum, B. adolescentis and B. bifidum were largely reduced in all of the patients, they showed to be present to a much larger degree in the control subjects. In fact, the species B. bifidum was present only in the group of control subjects, whereas the species B. adolescentis and B. longum were present to a larger degree in the control subjects and at a lower concentration in the obese and NASH groups (Figure 2).
An increase in the species of Lactobacillus in patients with NASH and NAFL
compared to the control subjects was demonstrated in this study. These data are in disagreement with a previous experimental study demonstrating that the administration of a probiotic based on Lactobacillus johnsonii to rats fed a high-fat diet (HFD) was capable of preventing the development of NAFLD (Ren T, Huang C, Cheng M.
"Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats" by affecting SIRT1-mediated signaling pathway. Oxid Med Cell Longev. 2014;2014:469059).
The discrepancy between these results and the present study may be attributed to a specific activity of lactobacilli or the use of animal models that may not fully reflect human beings. It is interesting to note that all of the obese patients enrolled in the present study showed a significant reduction in the presence of bifidobacteria compared to the control subjects, thus suggesting a possible role of bifidobacteria in this disease as well. Their role in obesity is in fact a matter of controversy, with some studies demonstrating an involvement thereof in increases in body weight and others showing opposite results. In particular, the strains of the species B. longum showed to be particularly capable of reducing increases in weight and body fat in a group of rats fed a high-fat diet for 5 weeks.
The species of Lactobacillus showed to be associated with both normal weight and obesity.
In conclusion, it was demonstrated that the strains of probiotic bifidobacteria, in particular the strains of probiotic bacteria belonging to the species Bifidobacterium adolescentis, Bifidobacterium bifidum and Bifidobacterium Ion gum and lactobacilli may influence NAFLD in a different way (Table 1).
Table 1 Bifidobacteria and lactobacilli: influence on NAFLD
Positive (X) or negative (0) influence Lactobacillus brevis 0 Lactobacillus ruminis 0 Lactobacillus zeae 0 Lactobacillus mucosae 0 Lactobacillus vagina//s 0 Bifidobacterium bifidum X
Bifidobacterium longum X
Bifidobacterium adolescentis X
Based on the results of this study, which ascertained the absence of certain species of Bifidbacterium in subjects affected by, or at a risk of developing NASH, NAFL and obesity and the presence of the same species in healthy not-at-risk subjects, it was surprisingly found that several species of Bifidobacterium, namely, the species B. adolescent/s, B. longum and B. bifidum, may have a role in protecting against the development of NASH, NAFL and obesity, in view of their significant reduction in patients affected by such disorders.
The administration of specific suitably selected strains of B. adolescent/s, B. longum and B. bifidum, individually or in combination with Oscillospira, may improve the symptoms and clinical course of NAFLD, especially in obese subjects of paediatric age (0-18, preferably 1-14 years);
said specific bacterial strains are preferably the ones indicated above as (i) to (vi) and the compositions of interest of the present invention are the ones indicated above as C, Cl, 02, C3 and C4.
In the context of the present invention, "enlarged liver", or hepatomegaly, means an increase in the size of the liver compared to what is judged clinically normal for an individual; it may be detected, for example, by palpation, exams with techniques such as ultrasound or computed tomography (CT) and/or blood tests.
The compositions for use according to the present invention, such as, for example, compositions Cl, 02 and 03 can be advantageously used, moreover, in obese or overweight subjects, according to the definition of the World Health Organisation, i.e. with a body mass equal to or greater than 25 to 29.99 (overweight) or equal to or greater than 30 (obese), preferably in paediatric age.
In one aspect of the invention, the composition (C), such as, for example, compositions Cl, C2 and C3, are administered to subjects at the risk of developing NAFLD and/or NASH, even if they do not yet have all the symptoms of said pathologies.
Preferably, the composition (C), such as, for example, compositions Cl, 02 and 03 for use according to the present invention, comprise a mixture of bacterial strains belonging to a species selected from the group consisting of, or, alternatively, comprising each species Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum, i.e. in which bacteria of at least all said species are present.
Preferably, the composition (C), such as, for example, compositions Cl, 02 and 03 for use according to the invention, may further comprise bacterial strains belonging to the genus Oscillospira.
In one aspect, the present invention provides a pharmaceutical preparation or medical device or food supplement comprising a composition (C) which comprises (i) a mixture of at least one bacterial strain belonging to at least one species selected from among the group comprising, or, alternatively, consisting of, bacteria belonging to at least one species among Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum and (ii) at least one excipient suitable for pharmaceutical and/or food use.
Preferably, in the pharmaceutical preparation or medical device or food supplement according to the present invention, the mixture (i) of the composition (C), such as, for example, of compositions Cl, 02 and 03, comprises a mixture of bacterial strains belonging to a species selected from the group consisting of or, alternatively, comprising each species Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum, and (ii) at least one excipient suitable for pharmaceutical and/or food use, i.e.
where bacteria belonging to at least each of said species are present.
Preferably, in the pharmaceutical preparation or medical device or food supplement according to the present invention, the mixture (i) of the composition (C), such as, for example, of compositions Cl, 02 and 03, further comprises bacteria belonging to the genus Oscillospira .
The at least one excipient (ii) suitable for pharmaceutical and/or food use may be selected from among all the substances known to the person skilled in the pharmaceutical field or the field of food preparations, including, as non-limiting examples, preservatives, thickeners, sweeteners, colourants, natural and artificial flavouring, antioxidants, stabilisers, fillers and mixtures thereof.
In the context of the present invention, the pharmaceutical preparation or medical device or food supplement may further comprise at least one pharmaceutically active ingredient or bacteria belonging to a species other than Bifidobacterium Ion gum, Bifidobacterium adolescentis and Bifidobacterium bifidum .
The following examples are provided to illustrate practical aspects of implementation, without any intention of limiting the scope hereof.
Bifidobacteria and lactobacilli were analysed by pyrosequencing of 16S rRNA in stool samples taken from 61 obese children with NAFL and NASH and 54 healthy controls.
Three species of Bifidobacterium (Bifidobacterium Ion gum, Bifidobacterium bifidum, Bifidobacterium adolescentis) and five species of Lactobacillus (Lactobacillus zeae, Lactobacillus vaginalis, Lactobacillus brevis, Lactobacillus ruminis, Lactobacillus mucosae) were frequently found in the metagenomic analyses.
The species of Lactobacillus were in greater number in the subjects affected by NAFL, with or without NASH, than in the controls, whilst bifidobacteria were frequent in healthy subjects.
MATERIALS AND METHODS
The study was conducted on 61 consecutive overweight or obese children (35 males, age 11.45 2.42 years) monitored at the Department of Hepato-Metabolic Diseases (Rome, Italy) of the Bambino Gesu Paediatric Hospital and Research Institute (OPBG) in 2013. All patients underwent testing for secondary causes of fatty liver, such as hepatitis, cytomegalovirus and Epstein-Barr viral infections, liver disease, autoimmune diseases, metabolic liver disease, Wilson's disease, coeliac disease and alpha-1-antitrypsin deficiency, which were ruled out using standard histological, laboratory and clinical criteria. Fifty-three patients, with a BMI>95th percentile, and/or hypertransaminasaemia and steatosis, underwent a liver biopsy for the assessment of liver damage. The study population was made up of 3 groups: 8 (13.12%) obese, 27 (44.26%) with NAFLD and 26 (42.62%) with defined NASH. Furthermore, 54 healthy children of a corresponding age, enrolled at the Human Microbiome Unit of the OPBG, were used as controls (control subjects).
The hospital's research ethics committee approved the study, which was conducted in conformity with the Declaration of Helsinki (according to the revision of Seoul, Korea, October 2008). The parents of the enrolled subjects gave informed written consent. The study was approved by the ethics committee of the OPBG (reference no. 768.12).
Stool samples were collected from all of the affected children and control subjects and analysed at the Human Microbiome Unit of the OPBG.
Anthropometric and laboratory analyses Anthropometric parameters including weight, height, BMI and waist circumference were measured in all of the children using standardised methods. Obesity was defined as a BMI 95th percentile, adjusted for age and sex according to WHO growth graphs. Fasting plasma glucose (FPG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), y-glutamyltransferase (GGT), fasting serum triglycerides (TG) and total cholesterol levels were determined using standardised methods in our laboratory. Insulin was measured by means of radioimmunoassay (MYRIA Technogenetics, Milan, Italy).
The degree of insulin resistance/sensitivity was determined by evaluating the homeostatic model (HOMA).
A HOMA value > 2 was considered indicative of insulin resistance.
All of the patients underwent abdominal ultrasound examination.
Designated expert radiologists, unaware of the clinical conditions of the patients, performed a liver ultrasound scan after overnight fasting.
The liver was analysed in terms of fatty liver markers using established criteria: a bright liver echostructure (compared with the echo response of the right kidney).
DNA extraction Each stool sample collected from the 115 children underwent a further metagenomic analysis having 16S-rRNA as the target. DNA was extracted from each sample using the QIAamp DNA
Stool Mini Kit (Qiagen, Germany).
The stools were resuspended in 1.5 ml PBS, rendered homogeneous by mixing for 2 minutes and centrifuged at 20,800xg. After removal of the supernatant, the sediment was resuspended in 500 pl of PBS, to which 500 pl of beads/PBS were added (1 mg/pl, w/v) (acid-washed glass beads, SigmaAldrich).
The supernatant was collected and treated for one freeze/thaw cycle (-20 0/70 C) for 20 minutes in each phase as previously described. After centrifugation at 5,200xg for 5 minutes, the supernatant was subjected to extraction with the QIAamp DNA Stool Mini Kit (Qiagen, Germany) according to the manufacturer's instructions and subsequently subjected to a metagenomic analysis pipeline. The intestinal microbiome was examined by pyrosequencing the V1-V3 regions of the 16S rRNA
gene (amplicon size 520 bp), on a GS Junior platform (454 Life Sciences, Roche Diagnostics, Italy).
Results The analysis revealed a prevalent distribution of 3 main species of Bifidobacterium (Bifidobacterium Ion gum, Bifidobacterium bifidum, Bifidobacterium adolescentis) and 5 species of Lactobacillus (Lactobacillus zeae, Lactobacillus vagina/is, Lactobacillus brevis, Lactobacillus ruminis, Lactobacillus mucosae), which appeared in a different manner in the targeted metagenomic analyses. In particular, L.
zeae was present in all four groups (i.e. obese, control ¨CTRL-, NAFL and NASH
children), whereas L
ruminis and L. vagina/is were present only in the NAFL and NASH groups. L.
mucosae was associated with obesity and NAFL, and L. brevis with NASH and control subjects (Figure 1).
In contrast, an inverse correlation was observed between bifidobacteria and NAFL and NASH; in particular, although the species B. Ion gum, B. adolescentis and B. bifidum were largely reduced in all of the patients, they showed to be present to a much larger degree in the control subjects. In fact, the species B. bifidum was present only in the group of control subjects, whereas the species B. adolescentis and B. longum were present to a larger degree in the control subjects and at a lower concentration in the obese and NASH groups (Figure 2).
An increase in the species of Lactobacillus in patients with NASH and NAFL
compared to the control subjects was demonstrated in this study. These data are in disagreement with a previous experimental study demonstrating that the administration of a probiotic based on Lactobacillus johnsonii to rats fed a high-fat diet (HFD) was capable of preventing the development of NAFLD (Ren T, Huang C, Cheng M.
"Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats" by affecting SIRT1-mediated signaling pathway. Oxid Med Cell Longev. 2014;2014:469059).
The discrepancy between these results and the present study may be attributed to a specific activity of lactobacilli or the use of animal models that may not fully reflect human beings. It is interesting to note that all of the obese patients enrolled in the present study showed a significant reduction in the presence of bifidobacteria compared to the control subjects, thus suggesting a possible role of bifidobacteria in this disease as well. Their role in obesity is in fact a matter of controversy, with some studies demonstrating an involvement thereof in increases in body weight and others showing opposite results. In particular, the strains of the species B. longum showed to be particularly capable of reducing increases in weight and body fat in a group of rats fed a high-fat diet for 5 weeks.
The species of Lactobacillus showed to be associated with both normal weight and obesity.
In conclusion, it was demonstrated that the strains of probiotic bifidobacteria, in particular the strains of probiotic bacteria belonging to the species Bifidobacterium adolescentis, Bifidobacterium bifidum and Bifidobacterium Ion gum and lactobacilli may influence NAFLD in a different way (Table 1).
Table 1 Bifidobacteria and lactobacilli: influence on NAFLD
Positive (X) or negative (0) influence Lactobacillus brevis 0 Lactobacillus ruminis 0 Lactobacillus zeae 0 Lactobacillus mucosae 0 Lactobacillus vagina//s 0 Bifidobacterium bifidum X
Bifidobacterium longum X
Bifidobacterium adolescentis X
Based on the results of this study, which ascertained the absence of certain species of Bifidbacterium in subjects affected by, or at a risk of developing NASH, NAFL and obesity and the presence of the same species in healthy not-at-risk subjects, it was surprisingly found that several species of Bifidobacterium, namely, the species B. adolescent/s, B. longum and B. bifidum, may have a role in protecting against the development of NASH, NAFL and obesity, in view of their significant reduction in patients affected by such disorders.
The administration of specific suitably selected strains of B. adolescent/s, B. longum and B. bifidum, individually or in combination with Oscillospira, may improve the symptoms and clinical course of NAFLD, especially in obese subjects of paediatric age (0-18, preferably 1-14 years);
said specific bacterial strains are preferably the ones indicated above as (i) to (vi) and the compositions of interest of the present invention are the ones indicated above as C, Cl, 02, C3 and C4.
Claims (10)
1. Bacterial strains belonging to the species B. adolescentis selected from the group comprising, or consisting of:
- (i) Bifidobacterium adolescentis BA06, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32479; and - (ii) Bifidobacterium adolescentis BAN, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 21.4.2017 and having the deposit no. 32491.
- (i) Bifidobacterium adolescentis BA06, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32479; and - (ii) Bifidobacterium adolescentis BAN, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 21.4.2017 and having the deposit no. 32491.
2. Bacterial strains belonging to the species B. bifidum selected from the group comprising, or consisting of:
- (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32480; and - (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32481.
- (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32480; and - (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32481.
3. Bacterial strains belonging to the species B. longum selected from the group comprising, or consisting of:
- (v) Bifidobacterium longum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32482; and - (vi) Bifidobacterium longum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32483.
- (v) Bifidobacterium longum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32482; and - (vi) Bifidobacterium longum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32483.
4. The bacterial strains according to any one of claims 1-3, wherein said bacterial strains belonging to the species Bifidobacterium adolescentis, Bifidobacterium bifidum and Bifidobacterium longum are for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to, metabolic syndrome, enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject; said treatment preferably comprises oral administration of said strains to the subject.
5. A composition (C) which comprises an effective amount of a mixture comprising, or consisting of, at least one bacterial strain selected from among the bacterial strains belonging to the species B.
adolescentis selected from the group comprising, or consisting of:
- (i) Bifidobacterium adolescentis BA06, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32479; and - (ii) Bifidobacterium adolescentis BAN, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 21.4.2017 and having the deposit no. 32491; or from among the bacterial strains belonging to the species B. bifidum selected from the group comprising, or consisting of:
- (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32480; and - (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32481; or from among the bacterial strains belonging to the species B. longum selected from the group comprising, or consisting of:
- (v) Bifidobacterium longum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32482; and (vi) Bifidobacterium longum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A.
on 7.4.2017 and having the deposit no. 32483;
for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to, metabolic syndrome, enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject, wherein said treatment comprises oral administration of said composition (C) to the subject.
adolescentis selected from the group comprising, or consisting of:
- (i) Bifidobacterium adolescentis BA06, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32479; and - (ii) Bifidobacterium adolescentis BAN, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 21.4.2017 and having the deposit no. 32491; or from among the bacterial strains belonging to the species B. bifidum selected from the group comprising, or consisting of:
- (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32480; and - (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32481; or from among the bacterial strains belonging to the species B. longum selected from the group comprising, or consisting of:
- (v) Bifidobacterium longum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32482; and (vi) Bifidobacterium longum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A.
on 7.4.2017 and having the deposit no. 32483;
for use in the preventive and/or curative treatment of symptoms and/or pathologies deriving from, or connected to, metabolic syndrome, enlarged liver, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a subject, wherein said treatment comprises oral administration of said composition (C) to the subject.
6. The composition (C) for use according to claim 5, wherein the subject is of an age comprised between 0 and 18 years, preferably between 1 and 14 years.
7. The composition (C) for use according to one of the preceding claim 5 or 6, wherein the composition further comprises bacterial strains belonging to the genus Oscillospira.
8. A pharmaceutical preparation or medical device or food supplement comprising a composition (C) which comprises (I) an effective amount of a mixture comprising, or consisting of, at least one bacterial strain selected from among the bacterial strains belonging to the species B.
adolescentis selected from the group comprising, or consisting of:
- (i) Bifidobacterium adolescentis BA06, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32479; and - (ii) Bifidobacterium adolescentis BAN, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 21.4.2017 and having the deposit no. 32491; or from among the bacterial strains belonging to the species B. bifidum selected from the group comprising, or consisting of:
- (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32480; and - (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32481; or from among the bacterial strains belonging to the species B. longum selected from the group comprising, or consisting of:
- (v) Bifidobacterium longum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32482; and (vi) Bifidobacterium longum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A.
on 7.4.2017 and having the deposit no. 32483; and (II) at least one excipient suitable for pharmaceutical and/or food use.
adolescentis selected from the group comprising, or consisting of:
- (i) Bifidobacterium adolescentis BA06, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32479; and - (ii) Bifidobacterium adolescentis BAN, deposited with the Institute DSMZ
in Germany by Probiotical S.p.A. on 21.4.2017 and having the deposit no. 32491; or from among the bacterial strains belonging to the species B. bifidum selected from the group comprising, or consisting of:
- (iii) Bifidobacterium bifidum BB07, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32480; and - (iv) Bifidobacterium bifidum BB08, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32481; or from among the bacterial strains belonging to the species B. longum selected from the group comprising, or consisting of:
- (v) Bifidobacterium longum BL22, deposited with the Institute DSMZ in Germany by Probiotical S.p.A. on 7.4.2017 and having the deposit no. 32482; and (vi) Bifidobacterium longum BL23, deposited with the Institute DSMZ in Germany by Probiotical S.p.A.
on 7.4.2017 and having the deposit no. 32483; and (II) at least one excipient suitable for pharmaceutical and/or food use.
9. The pharmaceutical preparation or medical device or food supplement according to claim 8, wherein the mixture (i) of the composition (C) comprises bacterial strains belonging to a species selected from the group consisting of or, alternatively, comprising each of the species Bifidobacterium longum, Bifidobacterium adolescentis and Bifidobacterium bifidum.
10. The pharmaceutical preparation or medical device or food supplement according to claim 8 or 9, wherein the mixture (i) of the composition (C) further comprises bacteria belonging to the genus Oscillospira.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000109507 | 2016-10-28 | ||
| IT102016000109507A IT201600109507A1 (en) | 2016-10-28 | 2016-10-28 | COMPOSITION FOR THE PREVENTIVE OR CURATIVE TREATMENT OF LIVER DISORDERS |
| PCT/IB2017/056728 WO2018078599A2 (en) | 2016-10-28 | 2017-10-30 | Composition for the preventive or curative treatment of liver disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3041599A1 true CA3041599A1 (en) | 2018-05-03 |
Family
ID=58228400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041599A Abandoned CA3041599A1 (en) | 2016-10-28 | 2017-10-30 | Composition for the preventive or curative treatment of liver disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190336547A1 (en) |
| EP (1) | EP3532081B1 (en) |
| JP (1) | JP2019534013A (en) |
| KR (1) | KR20190072613A (en) |
| CN (1) | CN110418836A (en) |
| BR (1) | BR112019008370A2 (en) |
| CA (1) | CA3041599A1 (en) |
| ES (1) | ES2963178T3 (en) |
| IT (1) | IT201600109507A1 (en) |
| MA (1) | MA46634A (en) |
| RU (1) | RU2019115476A (en) |
| WO (1) | WO2018078599A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020323825B2 (en) * | 2019-07-30 | 2024-05-09 | Kobiolabs, Inc. | Kit for predicting or diagnosing nonalcoholic fatty liver disease, and method for diagnosing nonalcoholic fatty liver disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6132710A (en) * | 1997-03-17 | 2000-10-17 | Probiotix, Inc. | Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof |
| US20020013270A1 (en) * | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| JP5592439B2 (en) * | 2012-06-13 | 2014-09-17 | 雪印メグミルク株式会社 | Preventive, ameliorating, and therapeutic agents for metabolic disorders associated with aging |
| KR101545551B1 (en) * | 2013-12-12 | 2015-08-19 | 주식회사한국야쿠르트 | The composition containing combination of 7 probiotics which have efficacy preventing from insulin resistance which cause type 2 diabetes mellitus as a effector component |
| WO2015172191A1 (en) * | 2014-05-12 | 2015-11-19 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
| CA2964480A1 (en) * | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
-
2016
- 2016-10-28 IT IT102016000109507A patent/IT201600109507A1/en unknown
-
2017
- 2017-10-30 MA MA046634A patent/MA46634A/en unknown
- 2017-10-30 US US16/345,680 patent/US20190336547A1/en not_active Abandoned
- 2017-10-30 BR BR112019008370A patent/BR112019008370A2/en not_active IP Right Cessation
- 2017-10-30 KR KR1020197014838A patent/KR20190072613A/en not_active Application Discontinuation
- 2017-10-30 JP JP2019522957A patent/JP2019534013A/en active Pending
- 2017-10-30 WO PCT/IB2017/056728 patent/WO2018078599A2/en unknown
- 2017-10-30 ES ES17804944T patent/ES2963178T3/en active Active
- 2017-10-30 RU RU2019115476A patent/RU2019115476A/en not_active Application Discontinuation
- 2017-10-30 CN CN201780066839.7A patent/CN110418836A/en active Pending
- 2017-10-30 EP EP17804944.1A patent/EP3532081B1/en active Active
- 2017-10-30 CA CA3041599A patent/CA3041599A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2963178T3 (en) | 2024-03-25 |
| US20190336547A1 (en) | 2019-11-07 |
| WO2018078599A4 (en) | 2018-08-09 |
| IT201600109507A1 (en) | 2018-04-28 |
| MA46634A (en) | 2021-04-28 |
| CN110418836A (en) | 2019-11-05 |
| EP3532081A2 (en) | 2019-09-04 |
| WO2018078599A3 (en) | 2018-06-07 |
| EP3532081C0 (en) | 2023-08-30 |
| WO2018078599A2 (en) | 2018-05-03 |
| JP2019534013A (en) | 2019-11-28 |
| RU2019115476A (en) | 2020-11-30 |
| EP3532081B1 (en) | 2023-08-30 |
| BR112019008370A2 (en) | 2019-07-09 |
| KR20190072613A (en) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kobyliak et al. | A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial | |
| Nobili et al. | Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? | |
| Mofidi et al. | Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial | |
| Scorletti et al. | Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease | |
| Mobini et al. | Metabolic effects of L actobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial | |
| Damms-Machado et al. | Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction | |
| Wang et al. | Bifidobacteria exert species-specific effects on constipation in BALB/c mice | |
| Manzhalii et al. | Treatment efficacy of a probiotic preparation for non‐alcoholic steatohepatitis: a pilot trial | |
| Rahman et al. | Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol | |
| Singh et al. | Lactobacillus rhamnosus NCDC17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats | |
| Barbara et al. | The intestinal microenvironment and functional gastrointestinal disorders | |
| Sharafedtinov et al. | Hypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients-a randomized double-blind placebo-controlled pilot study | |
| Eslamparast et al. | Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study | |
| Gøbel et al. | Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome | |
| Zheng et al. | Lactobacillus rhamnosus FJSYC4-1 and Lactobacillus reuteri FGSZY33L6 alleviate metabolic syndrome via gut microbiota regulation | |
| US10000818B2 (en) | Prevention and diagnosis of visceral fat | |
| Zhou et al. | Milk polar lipids modulate lipid metabolism, gut permeability, and systemic inflammation in high-fat-fed C57BL/6J ob/ob mice, a model of severe obesity | |
| Roselli et al. | Beneficial effects of a selected probiotic mixture administered to high fat-fed mice before and after the development of obesity | |
| Oo et al. | Safety and long-term effect of the probiotic FK-23 in patients with hepatitis C virus infection | |
| Wang et al. | Bifidobacterium longum relieves constipation by regulating the intestinal barrier of mice | |
| Hong et al. | Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function | |
| Chiu et al. | Probiotic actions on diseases: implications for therapeutic treatments | |
| Escouto et al. | Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: a randomized controlled trial | |
| EP3532081B1 (en) | Composition for the preventive or curative treatment of liver disorders | |
| AU2017100632A4 (en) | An oral liquid probiotic formulation and method of preventing and/or treating arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230502 |
|
| FZDE | Discontinued |
Effective date: 20230502 |